Sign in Subscribe
Nanoparticles

Understanding the Physicochemical Properties of Lipid Nanoparticles for RNA-Based Therapies

Strategic Insights

— 1 min read

Researchers from Denmark have made significant progress in understanding the physicochemical properties-activity relationship for lipid nanoparticles (LNPs) carrying RNA-based therapies. The study, published in the Journal of Controlled Release, highlights the importance of the pKa value of instrumental ionizable lipids (ILs) in siRNA- and mRNA-loaded LNPs for high in vivo potency. The research concludes that ILs located in the LNP surface and core, bound or unbound to mRNA, exhibit different pKa values, which may explain the variability in potencies among ILs within the optimal TNS-derived pKa range.

Key Takeaways:

  • The pKa value of ILs is a critical parameter in determining the potency of siRNA- and mRNA-LNPs.
  • ILs located in the LNP surface and core exhibit different pKa values, which may explain the variability in potencies among ILs.
  • Computational methods can be used to determine the pKa value of ILs in LNPs.
  • The environmental impact on the pKa of ILs is significant, and internal features such as dynamic and structural packing of the ILs may facilitate efficient endosomal escape of nucleic acid payloads.
  • The research emphasizes the need for a better understanding of the physicochemical properties-activity relationship for LNPs carrying RNA-based therapies.

Statistics:

  • The study reports that the apparent pKa (pKa) of the instrumental ionizable lipids (ILs) in siRNA- and mRNA-loaded LNPs is a critical parameter for high in vivo potency.
  • The optimal pKa range for high potency is typically within a narrow range of pKa values derived from the TNS assay.
  • The study reveals a broad spectrum of potencies across ILs within this optimal pKa range.

Sources:

  • A perspective on the apparent pKa of ionizable lipids in mRNA-LNPs. Journal of Controlled Release, 2025:113879.
  • Journal of Controlled Release. Elsevier, Radarweg 29, 1043 Nx Amsterdam, Netherlands. (www.elsevier.com; www.journals.elsevier.com/journal-of-controlled-release/)
  • Jens B. Simonsen, Jbsimonsen Consult, 2830 Virum, Denmark.

Read more